Patent Application
20130310853
The disclosed subject matter relates generally to methods and apparatus for the percutaneous treatment of arterial and venous aneurysm, such as abdominal aortic aneurysm, suturing of tissue in various applications such as closure of arterial and venous puncture sites, suturing a graft anastomosis to an aperture in a vessel wall or other types of tissue, and the like, in which no surgical cut down is required.
A number of diagnostic and interventional vascular procedures are now performed transluminally, where a catheter is introduced to the vascular system at a convenient access location and guided through the vascular system to a target location using established techniques. Such procedures require vascular access which is usually established using the well known Seldinger technique, as described, for example, in William Grossman's “Cardiac Catheterization and Angiography,” 3rd Ed., Lea and Febiger, Philadelphia, 1986, incorporated herein by reference.
When vascular access is no longer required, the introducer sheath must be removed and bleeding at the puncture site stopped. One common approach to attempt providing hemostasis (the cessation of bleeding) is to apply external force near and upstream from the puncture site, typically by manual or “digital” compression. This approach suffers from a number of disadvantages. It is time-consuming, frequently requiring one-half hour or more of compression before hemostasis is assured. This procedure is uncomfortable for the patient and frequently requires administering analgesics to be tolerable. Moreover, the application of excessive pressure can at times totally occlude the underlying blood vessel, resulting in ischemia and/or thrombosis. Following manual compression the patient is required to remain recumbent for at least six and at times as long as eighteen hours under close observation to assure continued hemostasis. During this time renewed bleeding may occur resulting in bleeding through the tract, hematoma and/or pseudoaneurism formation as well as arteriovenous fistula formation. These complications may require blood transfusion and/or surgical intervention. The incidence of these complications increases when the sheath size is increased and when the patient is anti-coagulated. It is clear that the standard technique for arterial closure can be risky, and is expensive and onerous to the patient. While the risk of such conditions can be reduced by using highly trained individuals, such use is both expensive and inefficient.
To overcome the problems associated with manual compression, the use of bioabsorbable fasteners to stop bleeding has been proposed by several groups. Generally, these approaches rely on the placement of a thrombogenic and bioabsorbable material, such as collagen, at the superficial arterial wall over the puncture site. While potentially effective, this approach suffers from a number of problems. It can be difficult to properly locate the interface of the overlying tissue and the adventitial surface of the blood vessel, and locating the fastener too far from that surface can result in failure to provide hemostasis and subsequent hematoma and/or pseudo aneurism formation. Conversely, if the fastener intrudes into the arterial lumen, intravascular clots and/or collagen pieces with thrombus attached can form and embolize downstream causing vascular occlusion. Also, thrombus formation on the surface of a fastener protruding into the lumen can cause a stenosis which can obstruct normal blood flow. Other possible complications include infection as well as adverse reactions to the collagen implant.
Catheters are also used to treat heart disease which is a major medical ailment wherein arteries become narrowed or blocked with a build-up of atherosclerotic plaque or clot which reduces flow to tissues downstream or “distal” to the blockage. When this flow reduction becomes significant, a patient's quality of life may be significantly reduced. In fact, heart disease patients often die when critical arteries, such as the coronary arteries, become significantly blocked.
However, technology has been developed to open some blocked arteries in the treatment of heart disease. For example, balloon angioplasty has become a well accepted treatment wherein a balloon is inflated within the narrowed vessel to stretch or otherwise deform the blockage into a larger lumen. Attentively, the blockage can even be removed, such as in a procedure known as atherectomy. In general, these treatments use percutaneous catheters which are inserted into the patients' vessels at a peripheral artery or vein puncture site and guided to the internal blockage site via x-ray visualization. The blockage is then treated remotely by use of hydraulic pressure in the case of balloon angioplasty, or by other actuating means to cause remote cutting or ablation of the blockage in the case of atherectomy.
In the alternative to using catheters to treat heart disease, or when such catheterizations are contraindicated, some blocked vessels can be treated with coronary artery bypass graft surgery (“CABG”). In conventional CABG techniques, a tubular graft is affixed to a port or aperture in an artery wall distally of the blockage. When the opposite end of the tube is in fluid communication with a pressurized arterial blood supply, such as the aorta, the tubular graft provides a conduit for flow into the vessel lumen distally of the blockage.
Conventional CABG surgery is generally initiated by directly exposing the heart to the surgeon. This is accomplished by opening the patient's chest using known sternotomy and retraction techniques that cut the sternum and spread the rib cage open. Then, one or both lungs are usually deflated and the patient is connected to a respiratory assist machine.
Once the heart is exposed, the patient is connected to a coronary bypass machine so that the blood supply circumvents the heart. In this way, the heart is depressurized so that apertures can be cut into the walls of the vessels for surgical graft attachment. The right atrium (or vena cava) and the aorta each is intubated with cannulas which are connected to an artificial pump and oxygenator. Once these major vessels are cannulated, cardioplegia is delivered to slow or stop the beating motion of the heart. The aorta is then clamped proximally of the aortic bypass cannula, thereby isolating the proximal aortic root from the blood that is being circulated by the bypass machine.
After the heart is isolated from blood pressure, conventional bypass grafting is performed. The required grafts are implanted to feed the coronary arteries distal to the blockage, the clamp is removed from the aorta, the lungs are restored, and the patient is then taken off of the bypass pump.
In one type of CABG method, the bypass grafting is achieved between the aorta and one of the three major coronary arteries or their sub-branches, the left anterior descending artery (LAD), the circumflex artery (CIRC), or the right coronary artery (RCA). In such a case, a saphenous vein is usually taken from the patient's leg and is transplanted as a “homograft” to connect these vessels in the same patient's chest. Artificial grafts have also been disclosed as providing potential utility for this purpose and are herein collectively included in the general discussion of “saphenous veins” as used in CABG procedures.
An alternative CABG method uses the internal mammary artery (IMA) alone or in conjunction with the saphenous vein graft. The IMA is severed at a chosen location and is then connected to an aperture, in a coronary artery.
In either case of using saphenous vein homografts or artificial grafts in CABG surgery, the proximal end of the graft is generally sutured or otherwise is affixed circumferentially to the tissue surrounding an aperture that is punched into the wall of the aorta. In this arrangement, the lumen of the graft communicates with the vessel through the aperture, wherein ideally the aperture approximates the inner diameter of the graft lumen. The opposite, distal end of the graft is sutured to an aperture formed in the wall of the coronary vessel distal to the blockage.
The fluid connections between a graft and a vessel are herein referred to as “anastomoses.” In the instance of CABG, “proximal anastomoses” and “distal anastomoses” are terms used when referring to grafting to the aorta and the coronary artery, respectively. In most CABG procedures using saphenous vein grafts, the distal anastomosis is performed first, followed by the proximal anastomosis.
For the CABG method using the IMA, only one distal anastomosis is formed distal to the arterial blockage. A proximal anastomosis to the aorta is not required as it is in a saphenous vein graft procedure because the IMA's natural arterial blood flow feeds the heart.
In conventional CABG surgery methods such as those just summarized, the timing and technique of the anastomosis procedures are critical factors to procedural success. In fact, it is believed that three critical determinants which affect outcomes of CABG surgery are: (1) time the patient spends on bypass, (2) time the patient spends with a clamped aorta, and (3) the quality of the anastomoses. It is generally believed that a CABG patient's operative and peri-operative morbidity are directly related to how long the patient must be on heart bypass. In fact, it is generally understood that the risk of patient morbidity is believed to rise significantly after a threshold time of one hour on bypass. Perhaps the most prevalent complication arising from prolonged cardiac bypass is the high risk of distal thrombus created by the artificial plumbing. For example, such thrombi can embolize into the neurovasculature and potentially can cause a stroke. In analyzing the timing of individual CABG steps against the backdrop of a patient's critical time on bypass, the time spent anastomosing the grafts to vessels emerges as a controlling factor. The average time for suturing one anastomosis is approximately 7-10 minutes. Furthermore, it is believed that an average CABG procedure involves approximately five anastomoses: two saphenous vein grafts, each with a proximal and a distal anastomosis, and one internal mammary artery having only one distal anastomosis. Therefore, the average time for graft suturing ranges from 35 minutes to 50 minutes—in any case a significant portion of the 60 minute critical threshold to patient morbidity. Closely related to the time spent on bypass is a second CABG success factor related to the extent and time of aortic cross-clamping. It is believed that the inherent crushing force from a cross-clamp across the bridge of the muscular aortic arch may be associated with a high degree of tissue trauma and structural damage. Additionally, hemostasis formed at or adjacent to the cross clamp, perhaps in conjunction with the tissue trauma of clamping, may also be a source of unwanted thrombogenesis.
In addition to the timing of anastomosing grafts and extent and duration of aortic cross-clamping, the quality of interface between the graft and vessel is also believed to be an indicator of procedural success. The accuracy, trauma, and repeatability of suturing, as well as the three-dimensional interface formed between the conduits at the anastomosis site, are significant variables in conventional manual surgical techniques. These variables are believed to significantly affect the short or long-term success of conventional CABG anastomosis procedures.
Both of the critical CABG success indicators summarized above—time on cardiac bypass and quality of anastomosis suturing—are directly affected by inherent limitations in the devices used in conventional CABG procedures. It is believed that improvements to these devices and related methods of use may provide for more rapid and reliable vessel-graft anastomosing. For example, conventional “surgical punches” are devices that cut or “punch” a plug in vessel wall tissue to form an aperture in the wall. In a CABG procedure, the tissue surrounding a punched-out aperture provides the substrate upon which a graft may be sutured to form an anastomosis. One procedural limitation in using conventional surgical punches is that hemostasis can not be maintained at a vessel wall after a plug of tissue is punched out and removed. Therefore, an aperture in an aortic wall during a saphenous vein graft procedure can only be made when that portion of the aorta is cross-clamped, bypassed, and depressurized. Otherwise, the high blood pressure and flow in the aorta would cause significant bleeding during the period from punching the aperture to forming the anastomosis. Because of this limitation in conventional surgical punches, the threshold 60 minute coronary bypass clock begins running before punching the aorta.
The prior art fails to disclose or fulfill the need which exists in the field of medical devices and methods for: suturing tissue by proximally drawing sutures through a tissue layer in the proximity of an aperture; suturing tissue by reversibly advancing needles from one side of a tissue layer to retrieve one or more sutures on the opposite side of the tissue layer; a medical device assembly and method that automatically and repeatably places suture thread through vessel wall tissue surrounding an aperture in the vessel wall in a suture pattern that is useful for anastomosing a tubular graft to the aperture; and a medical device assembly that deploys a suture with one end extending through the tissue that surrounds a aperture in a vessel wall and the opposite suture end extending radially through a tubular graft wall adjacent an open end of the graft, such that a vessel anastomosis may be rapidly and repeatably performed in a CABG procedure even while the vessel is under physiological flow.
The prior art likewise fails to disclose a medical device or method to overcome anatomical challenges associated with a totally endoscopic technique. Among these challenges are calcification of the vessel, groin scarring/recent catheterization, and patient obesity. Prior published experience suggests that significant ipsilateral groin scarring and morbid obesity are suitable exclusionary conditions. Other predictors included larger sheath size and pre-existing groin scarring (odds ratios 1.2 and 8.2, respectively, P<0.05). Groin scarring was a significant predictor of late access-related intervention (odds ratio 49, P<0.001).
In patients with suitable anatomy for an endoluminal stent graft, endovascular abdominal aortic aneurysm repair (“EVAR”) has become an appealing alternative to open surgical repair due to its low perioperative morbidity and mortality. Moreover, device improvements have led to the expansion of the patient population in which EVAR may be offered, either through a wider range of stent graft sizes, improved materials, or smaller catheter based access sheaths.
Currently in the United States, endograft device labeling indicates the introduction of the main device (ranging from a profile of 8 Fr to 26 Fr) through surgical vascular exposure of the ipsilateral common femoral artery (CFA). Endovascular grafting has markedly reduced the invasiveness of the treatment of abdominal aortic aneurysms; it has reduced the length of hospital stays, intensive care requirements and operative morbidity.
It is often desirable to provide additional treatment for the access site when positioning the sutures and closing the opening in the vessel. What is needed is a apparatus for applying coated sutures for administering a medication to the vessel tissue. Moreover, what is needed is an a apparatus for adjustment of the spacing between needles during the positioning of sutures through the vessel tissue.
The present invention provides a totally percutaneous method of treating an affected region of a blood vessel, the method including creating an access point in a blood vessel of a patient proximal to the affected site without a surgical cut-down procedure; advancing a guidewire through the access point and traversing the guidewire to a location distal to the affected site; advancing a closure device into the blood vessel; selectively adjusting the spacing of a plurality of needles; advancing the needles through a wall of the blood vessel thereby positioning a suture through the wall of the blood vessel across the access point; removing the closure device from the subject; delivering an medical device to the location of the affected site; and securing the suture to close the access point of the blood vessel.
In some embodiments, the method includes providing two or more needles having a first pre-curved configuration and a second straightened configuration, and wherein selectively adjusting the spacing of the needles comprises withdrawing a sheath surrounding the needles thereby permitting the needles to move from the second configuration to the first configuration. In some embodiments, the spacing of the plurality of needles is adjustable between about 8 Fr and about 24 Fr.
In some embodiments, the blood vessel is a vein. In some embodiments, the suture is coated with a hydrogel, an antibiotic, a pro-coagulent medication, and/or an anti-inflammatory medication.
In some embodiments, advancing the closure device into the blood vessel includes advancing the closure device at an angle of about 45° relative to the blood vessel. In some embodiments, the method further includes dilating the blood vessel prior to insertion of the closure device.
In some embodiments, the closure device includes a shaft having a proximal end and a distal end and defining an axis therebetween; an elongate foot movably mounted to the shaft, the foot supporting the suture; an actuator extending along the shaft distally to the foot, movement of the actuator pivoting the foot from a low profile configuration aligned along the shaft to a deployed configuration extending laterally from the shaft; and a needle advanceable from the shaft through the tissue and to the deployed foot.
In some embodiments, the needle has a proximal end and a distal end suitable for forming a first needle path through the vessel wall; and a first fitting attached to the suture, the first fitting securingly engaging the first needle when the first needle advances through the vessel wall so that the first fitting and at least a portion of the suture can be withdrawn proximally along the first needle path by the first needle.
In some embodiments, the foot has a first end and a second end, wherein a plurality of needles are extendable from the shaft to the ends of the foot.
In some embodiments, the suture is a monofilament suture.
In some embodiments, positioning a suture through a wall of the blood vessel across the access point includes positioning the suture through the wall of the blood vessel at first angle with respect to the longitudinal axis of the patient; and further comprising after removing the first closure device from the subject, advancing a second closure device into the blood vessel; positioning a second suture through a wall of the blood vessel across the access point at a second angle with respect to the longitudinal axis of the patient; removing the second closure device from the subject.
In some embodiments, the first angle is 60 degrees in a first direction from the longitudinal axis of the patient. In some embodiments, the second angle is 60 degrees in a second direction from the longitudinal axis of the patient.
A totally percutaneous method of treating an affected region of a blood vessel is provided, the method including creating an access point in a blood vessel of a patient proximal to the affected site without a surgical cut-down procedure; advancing a guidewire through the access point and traversing the guidewire to a location distal to the affected site; advancing a closure device into the blood vessel; positioning an anchor carrying a suture therewith through a wall of the blood vessel across the access point; deploying the anchor with respect to the wall of the blood vessel; removing the first closure device from the subject; delivering a medical device to the location of the affected site; and securing the suture to close the access point of the blood vessel.
In some embodiments, the blood vessel is a vein.
In some embodiments, the method further includes providing an anchor defining a longitudinal axis, a central opening for retaining a suture therein, and a notch extending from the central opening allowing the suture to pass from the central opening through the notch at an angle with respect to the longitudinal axis, and wherein deploying the anchor comprises withdrawing the suture from the vessel such that the anchor engages the wall of the vessel and the suture extends from the anchor at a angle with respect to the longitudinal axis of the anchor.
In some embodiments, the method further includes defining a plurality of vanes on the suture, and wherein deploying the anchor comprises engaging the vanes with the notch of the anchor and the vessel wall. In some embodiments, the method further includes defining a plurality of ridges on the notch for engaging the suture, and wherein deploying the anchor comprises engaging the suture with the ridges of the notch. In some embodiments, the anchor is fabricated from magnesium.
In some embodiments, the method further includes providing an anchor defining a longitudinal axis, a central opening for retaining a suture therein, and a plurality of longitudinal notches defining a plurality of grappler arms, and wherein deploying the anchor comprises withdrawing the suture from the vessel such that the plurality of grappler arms are displaced radially outwardly from the longitudinal axis and engage the wall of the vessel.
In some embodiments, the method further includes providing an anchor comprising a resilient strip having a first configuration defining a coil and a second straightened configuration, and wherein advancing a closure device into the blood vessel comprises restraining the resilient strip in the first configuration within an introducer.
In some embodiments, the method further includes positioning the anchor carrying a suture therewith through a wall of the blood vessel across the access point comprises advancing the introducer through the wall of the blood vessel with the resilient strip disposed therein.
In some embodiments, deploying the anchor with respect to the wall of the blood vessel includes advancing the resilient strip with respect to the introducer into the blood vessel, thereby allowing the resilient strip to return to the first configuration.
An apparatus for the percutaneous closure of an opening created in a blood vessel is provided including a shaft defining a bore therethrough for guidewire access; two or more needles defining a first configuration defining a curved configuration and a second straightened configuration; a sheath surrounding the needles and advanceable from a first position in which the needles are restrained in the second configuration and a second position in which the needles are permitted to return to the first configuration; and one or more sutures attached to an end portion of the needles.
In some embodiments, the sheath is sized to fit through an opening in the blood vessel of about 8 Fr. In some embodiments, the method further includes the sheath is sized to fit through an opening in the blood vessel of about 24 Fr. In some embodiments, the needle is fabricated from a shape memory alloy. In some embodiments, the needle is fabricated from nitinol. In some embodiments, the shaft and the sheath are flexible.
An apparatus for the percutaneous closure of an opening created in a blood vessel is provided including an anchor defining a longitudinal axis, a central opening for retaining a suture therein, and a notch extending from the central opening allowing the suture to pass from the central opening through the notch at an angle with respect to the longitudinal axis, a suture partially positioned within the central opening and retained therein, the suture partially extending from the central opening, an introducer for advancing through the wall of the vessel and accommodating the anchor therein.
In some embodiments, the suture defines a plurality of vanes thereon for engagement with the notch of the anchor and the vessel wall. In some embodiments, the notch defines a plurality of ridges for engaging the suture. In some embodiments, the anchor is fabricated from magnesium.
An apparatus for the percutaneous closure of an opening created in a blood vessel is provided including an anchor defining a longitudinal axis, a central opening for retaining a suture therein, and a plurality of longitudinal notches defining a plurality of grappler arms for engagement with the wall of the vessel; a suture partially positioned within the central opening and retained therein, the suture partially extending from the central opening; an introducer for advancing through the wall of the vessel and accommodating the anchor therein.
An apparatus for the percutaneous closure of an opening created in a blood vessel is provided including an anchor comprising a resilient strip having a first configuration defining a coil and a second straightened configuration, and wherein advancing a closure device into the blood vessel comprises restraining the resilient strip in the first configuration within an introducer, a suture partially positioned within the central opening and retained therein, the suture partially extending from the central opening, and an introducer for advancing through the wall of the vessel and accommodating the anchor therein in the first configuration and for deploying the anchor from therefrom in the second configuration.
In the drawings, which comprise a portion of this disclosure but are not to scale:
The term “distal” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, as in the direction of the patient, or away from a user of a device, or in a downstream direction relative to a forward flow of blood. In the context of a medical device intervention with or through a vessel wall, “distal” herein refers to the interior or the lumen side of the vessel wall.
The term “proximal” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, as away from the patient, or toward the user, or in an upstream direction relative to a forward flow of blood. In the context of a medical device intervention with or through a vessel wall, “proximal” herein refers to the exterior or outer side of the vessel wall.
The term “oblong” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, oval, elliptical, or otherwise having a generally rounded shape that is not perfectly circular. In particular, the term describes the shape of a tubular graft end cut at an acute angle relative to the plane perpendicular to the tissue walls defining the graft.
The term “hemostasis” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the arrest of bleeding or substantially blocking flow of blood outwardly from a vessel lumen while the vessel lumen is pressurized or sustaining physiological blood flow. This amount of blockage or occlusion to flow is further defined such that the blood loss which is experienced is less than an amount which would affect procedural methods or outcomes according to a physician user of a device of ordinary skill in the art. In other words, “hemostasis” is not intended to mean only “total hemostasis” such that there is a total lack of blood loss. Rather, the term is used to also mean “procedural hemostasis” as a relative term in its use among physicians of ordinary skill.
Similarly, the terms “occlusion,” “occlude,” “blockage,” “block . . . plugging”, “block,” or variations thereof are all terms which are herein intended to have a procedurally relevant definition in the context of their use. For instance, an aperture is “occluded” although there is some measurable flow therethrough, but that flow is so low such that the intended procedural benefit of occlusion is at least partially achieved. Certainly, such terms also properly include within their scope a “total effect” definition, as well.
The term “perfusion” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the flow of blood or other unit of perfusate (the fluid used for perfusion) per unit volume of tissue. Physiological perfusion refers to the amount of blood flow present when the body is functioning normally. For example, physiological perfusion usually prevents clinically significant ST elevations which is one of the most sensitive indicators of inadequate perfusion. Adequate perfusion refers to the amount of blood flow that avoids the clinical requirement of transfusing the patient or that is needed to prevent tissue necrosis distal to the aperture in the blood vessel.
The term “suturing” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the process of joining two surfaces or edges together with a fasten r so as to close an aperture, opening, or wound or join tissues. The fastener is usually a suture such as a thread of material (either polymeric or natural), gut, wire or the like. The term “fastener” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, also includes clamps, studs, hasps, catches, hooks, rivets, staples, snaps, stitches, VELCROC, buttons, and other coupling members.
The term “PEVAR” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, endovascular aneurysm repair using a bilateral access approach.
The term “pre-close” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the placement of the sutures in a blood vessel, e.g., femoral artery, before the arteriotomy is enlarged by an endovascular sheath.
The term “surgical cut-down” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the surgical exposure of the vessel for device introduction.
The term “procedural technical success” or “procedural success” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, successful vascular access, delivery of graft introducer catheter, e.g., IntuiTrak device delivery, deployment and catheter removal without vascular exposure.
The term “vascular complication” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, any of the following that requires medical or surgical intervention: arteriovenous fistula, femoral neuropathy, hematoma requiring drainage or other surgical intervention, infection, lymphocele, hemorrhage, vascular (iliac or femoral artery) injury or pseudoaneurysm requiring surgical repair; stenosis, distal emboli or thrombosis/occlusion of a peripheral artery or stent graft limb, and the like.
The term “major adverse event” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, all-cause death, conversion to open repair, aneurysm or blood vessel rupture, secondary intervention for type I or III endoleak; bowel ischemia; cardiac morbidity, neurological complications, renal failure, respiratory complications, and the like.
The term “time to hemostasis is defined as the elapsed time from sheath removal to first observed cessation of CFA bleeding (excluding cutaneous or subcutaneous oozing).
The term “device implant time” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the elapsed time between IntuiTrak sheath introduction and removal.
The term “procedure time” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the elapsed time from the first break of skin to final closure (i.e., skin to skin time).
The term “time to ambulation” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the elapsed time from sheath removal to the time when the patient stands and walks at least 20 feet without re-bleeding.
The disclosures of U.S. Pat. Nos. 5,304,184; 5,476,469; 5,720,757; 5,746,755; 5,797,929; 5,810,850; 6,117,145; 6,132,440; 6,136,010; 6,190,396; 6,348,059; 6,358,258; 6,558,399; 6,730,102; 6,746,457; 6,964,668; 7,001,400; 7,029,487; 7,048,747; 7,060,078; 7,094,246; 7,147,646; 7,201,762; 7,235,087; and 7,445,626; and U.S. Publication Nos. 2011/0288563; 2011/0218568; and 2010/0185234 are incorporated by reference herein for all purposes.
A suturing device, which delivers a pre-tied knot to an incision, is disclosed. As an overview, a suturing device in accordance with the present invention includes a first penetrator having a pre-tied knot disposed thereabout and a second penetrator having suture disposed thereon. During operation of the suturing device, the first penetrator and the second penetrator penetrate the tissue about a periphery of an incision in a body lumen. Upon penetration, a penetrator tip releasably engaged with the first penetrator couples with a foot of the suturing device. As the first and second penetrators retract from the body lumen, the penetrator tip and the suture coupled with the penetrator tip retract through a penetration formed in the body lumen by the first penetrator. As will be discussed in greater detail with reference to the accompanying Figures, as the suture refracts, the pre-tied knot receives the suture, forming a knot for suturing the incision in the body lumen.
Referring now to
As can be seen with reference to
Actuation of foot 24 is illustrated more clearly in
Actuation of foot handle 26 slides a foot actuation wire 32 proximally, pulling foot 24 from a parked position to the deployed position illustrated in
Shaft 12 also includes a foot position verification lumen that extends distally from a position verification port 36 to a position indicator at housing 18. When the foot is properly positioned within the blood vessel, blood pressure will cause blood to flow proximally through the indicator lumen to the indicator. The indicator may optionally comprise a blood exit port, a clear receptacle in which blood is visible, or the like. In the exemplary embodiment, the indicator of handle 18 comprises a length of clear tubing extending from housing 18 (not shown) in which the blood is clearly visible. It should be understood that a wide variety of alternative position verifications sensors might be used, including electrical pressure sensors, electrolytic fluid detectors, or the like.
The structures used in positioning a loop of suture across the puncture can be understood with reference to
To facilitate attachment of fitting 40 to suture 34, a second slot cut in the tubular fitting structure defines a suture attachment collar 50. Optionally, collar 50 may be crimped about suture 34 to mechanically affix the suture to fitting 40. In addition and/or instead of mechanical crimping, suture 34 may be bonded to fitting 40 using an adhesive, heat, fasteners, knots, or the like.
Fitting 40 is quite small in size, and is generally configured to facilitate withdrawing the fitting (and the attached suture) along with needle 38 axially through the vessel wall along the needle path. Needle 38 will generally have a cross-sectional width of between about 0.010 inches and 0.020 inches. Barb 42 will extend laterally so as to define an engagement surface 44 having a protruding length of between about 0.002 inches and 0.005 inches. Fitting 40 will preferably have a cross-sectional size roughly corresponding to or only slightly larger than needle 38. Fitting 40 will typically have an outer lateral width of between about 0.014 inches and 0.025 inches, and an axial length of between about 0.035 inches and 0.050 inches. Channel 46 will be sized to receive at least a portion of needle 38, and will generally have a width of between about 0.010 inches and 0.020 inches. Suture 34 will preferably extend axially opposite the open end of channel 46 so as to minimize drag when the suture is drawn proximally along the needle path. In the exemplary embodiment, needle 38 has a diameter of about 0.020 inches, while the fitting comprises a tube having an outer diameter of about 0.020 inches, an inner diameter of about 0.016 inches, and an overall length of about 0.047 inches. The fitting will typically comprise a resilient material, preferably comprising a metal, and in the exemplary embodiment, comprising stainless steel.
Needles 38 typically have a length of between about 5.0 inches and 6.0 inches, and will preferably be sufficiently stiff to be advanced in compression through the vessel wall (and adjacent tissues) for up to 0.5 inches when supported in cantilever. Nonetheless, the needles will ideally be flexible enough to be laterally deflected within shaft 12, as can be understood with reference to
As was generally described above, foot 24 includes needle receptacles 52 adjacent the ends of the foot. A fitting 40 (with an associated end of suture 34) is disposed within each needle receptacle, and a surface of the receptacle tapers proximally and outwardly so as to guide the advancing needles 38 into engagement with fittings 40 when foot 24 is in the deployed position. As fittings 40 (and associated portions of suture 34) are releasably supported in the foot, needles 38 can be withdrawn proximally so as to draw the fittings and suture ends from the foot proximally into (and optionally through) shaft 12. The needle receptacles of the exemplary embodiment taper outward at an angle between 20 and 35 degrees from the centerline of fitting 40, and the fitting is held in a recess having a diameter of about 0.0230 inches and a length of about 0.042 inches. A lateral opening or window through the side of foot to the fitting recess may be provided to facilitate needle and/or cuff positioning during assembly of the probe, and a protruding collar near the proximal end of the fitting recess may help keep the fitting in position.
One example of a suitable structure and articulation motion for foot 24 is illustrated in
Referring now to
A wide variety of foot actuation mechanisms might be used within the scope of the present invention. A first alternative foot actuation arrangement is illustrated in
A still further alternative foot actuation mechanism is illustrated in
Yet another foot actuation mechanism can be understood with reference to
A variety of features may be included in the articulatable foot, the needle receptacle, and/or the needle to avoid tangling of the needle in the suture as the needle is directed to the fitting. As illustrated in
An alternative mechanism for avoiding entanglement of the needle with the suture is illustrated in
A still further alternative mechanism for avoiding entanglement between the suture and the needle is illustrated in
An alternative vessel closure probe 70 will be explained with reference to
Referring now to
Bight 80 will define a knot when first end suture passes therethrough, as can be understood with reference to FIGS. 11Ai and 11Aii. Bight 80 will often include more than one loop, and may be pre-arranged so as to define a square knot (using the layout schematically illustrated in FIG. 11Ai), a clinch knot (FIG. 11Aii), or a variety of known or new surgical knots.
Probe 70 advances along tissue tract TT to puncture P in blood vessel V. Once foot 24 is disposed within a blood vessel V, a pull wire moves the foot proximally and pivots the foot laterally so that the foot extends along an axis A of the vessel, as illustrated in
As can be understood with reference to
It will be recognized that removal of probe 70 can be facilitated by coupling first end 76 to bight 80 over an outer surface of the probe, and by arranging suture 34 and hollow needle 38′ so that the suture can pull free of the needle when detachable tip 78 is released, for example, by having the suture exit the needle proximally of the tip through a channel that extends to the tip so that the needle does not encircle the suture. By including such provisions, after foot 24 is returned to the narrow configuration, the probe can be pulled proximally from the tissue tract leaving the pre-tied knot in place.
Alternative arrangements (using the detachable needle ends of probe 70) are possible to provide the benefit of a pre-tied knot and the like for closure of a vessel puncture. For example, a probe having a pair of needles in which each needle included a detachable tip might be used to pull first end 76 through a bight, so that the bight need not encircle the needle path of one of the needles.
In some cases, particularly for closure of large punctures, it may be advantageous to provide multiple suture loops across the puncture, either in parallel, in an “X” pattern, or the like. As illustrated in
The method of use of the probes of
Deployment of the foot is effected by actuation of the foot deployment handle, as described and illustrated above with reference to
Referring now to
Referring now to
Now referring to
The articulatable foot 114 includes anterior and posterior penetrator receptacles 116′ and 116, respectively. These receptacles are also referred to as cuff pockets. Cuffs 110 are shown positioned in cuff pockets 116′ and 116. A link 112 extends between the cuffs 110.
As may be seen with reference to
When both the elongate bodies 106 and 106′ and the suture 102 pass through the lumen wall W and into the lumen 107, the elongate bodies 106 and 106′ engage with the foot 114. The penetrator tip 108 and anterior penetrator tip 108′ of the elongate bodies 106 and 106′ engage with cuffs 110 and 110′ of the foot 114. The cuffs 110 and 110′ include a link 112 that connects the cuffs 110 and 110′ to one another. It should be noted that the cuffs 110 and 110′ facilitate connection of the penetrator tip 108 with the anterior penetrator tip 108′ such that the penetrator tip 108 and the anterior penetrator tip 108′ are coupled to one another via the link 112.
The ends of the suture may be distinguished from each other by changing the color of one end (e.g. with dye), providing an attachment on one end (e.g. shrink wrap tubing, a bead, etc.) or with the suture itself (e.g. tying a knot in one end).
Referring to
As the suture loop 103 and the suture 102 move, the pre-tied suture knot 104 also moves in the same direction as the suture loop 103 towards the foot 114 and the incision. The suture loop 103 continues to move the pre-tied suture knot 104 towards the incision until the suture 102 and the pre-tied suture knot 104 suture the incision formed in the arterial wall. It should be noted that a suture trimmer might be used to assist the delivery of the knot 104 to an arteriotomy. The suture trimmer may be any device suitable for pushing the knot towards the arteriotomy and trimming suture immediately adjacent the knot 104 once the knot is tightened.
Now making reference to
The ends may be distinguished from each other by changing the color of one end (e.g. with dye), providing an attachment on one end (e.g. shrink wrap tubing, a bead, etc.) or with the suture itself (e.g. tying a knot in on end).
Once the penetrator tip 308 engages with the cuff 310, the elongate body 306 and the penetrator tip 308, along with the cuff 310, proceed through the foot 314 and into the lumen 307. As may be seen with reference to
As shown in
In another embodiment shown in
In yet another alternate embodiment shown in
It should be noted that other methods might be used to detach the penetrator tip 308 from the elongate body 306. These methods include, but are not limited to, detachment through friction or tension. Making reference to
After detachment, during retraction of the elongate body 306 and the elongate body 306′ (not shown), the link 312 may draw the cuff 310 and the penetrator tip 308 from the cuff pocket 316. As discussed earlier, the cuff 310′ engages with the elongate body 306′ and pulls the cuff 310 via the link 312 as the elongate body 306′ retracts from the lumen 307. As such, retracting the link 312 pulls on the cuff 310, thereby pulling the cuff 310 from the cuff pocket 316 and through the lumen 307 along with the suture 302, as shown with respect to
Embodiments of the suturing device of the invention may also include additional configurations for a foot, as shown with reference to
In an embodiment of the present invention where the suturing device 300 employs the foot 319, during use of the suturing device 300, upon insertion of the suturing device 300 within the lumen 307, a user deploys the foot 319 as shown with reference to
Another embodiment of the suturing device 300 includes feet 324 and 328 as shown with reference to
During use of a suturing device implementing the feet 324 and 328, a user inserts the suturing device into an incision as the foot 328 resides within the foot 324. Upon insertion of the suturing device within the incision, the user deploys the feet 324 and 328 by moving the feet 324 and 328 towards the cam surfaces 326a, in order to deploy the feet 324 and 328, as previously described. After deployment of the feet 324 and 328 within a lumen, the user deploys the elongate bodies 306 and 306′ whereby the penetrator tip 308 and needle tip 308′ engage with the cuffs 310 and 310′ residing within the cuff pockets 324a and 328a. Upon engagement with the cuffs 310 and 310′ the user retracts the elongate bodies 306 and 306′ and sutures the incision.
In addition to the alternative configurations for the foot of the suturing device 300, the suturing device 300 may also include alternative cuff configurations that allow engagement of the elongate bodies 306 and 306′ with the link 312. An example of such an alternative configuration is shown with respect to
Referring to
In another embodiment, the suturing device 300 may also employ a clip and ring assembly 338 which couples the elongate bodies 306 and 306′ with the link 312, as shown with reference to
The clip and ring assembly 338 also includes a ring 334 that engages with the clip 336. The link 312 couples with the ring 334 using any suitable technique, such as tying or the like. The ring 334 has a circular configuration as shown with respect to
Referring to
To assemble the link and cuff assembly, a length of link material is first threaded through the cuff. The end of the link material extending from the penetrator tip receiving end 1434 of the cuff 1410 is then heated so that it expands. The link is then pull through the cuff 1410 such that the expanded end portion 1442 is seated in the interior tapered end 1432 of the cuff 1410.
Referring to
The device 400 comprises a guide body 402 and a needle shaft 404. The guide body 402 includes a guide tip 406 at its distal end, which guide tip includes a plurality of guide channels 408 which receive the proximal ends of needles 410. An aligning arrow 403 is mounted on handle 405 located at the proximal end of the guide body 402. A marker lumen bubble 407 is located below the aligning arrow and serves to indicate when the distal end of the guide body has entered a blood vessel, as described in the embodiment below. An indicator lumen 411 which permits the flow of blood to the marker lumen bubble 407 is illustrated in
The needles 410 as illustrated comprise a sharpened tip section 412 and an elongate shank portion 414, but may also be manufactured as an integral piece. The shank portion 414 will be sufficiently long so that the needles may be pushed from their butt end by a support holster 428 fixedly attached to the needle shaft 404 in order to advance the needles through the tissue to be sutured and fully through the guide body 402 inserted together with support sheath 440 in the associated tract so that no capture mechanism will be required.
The guide body 402 further includes a plurality of needle lumens 420 which are axially aligned and spaced about the periphery of the guide body. As best seen in
A flexible needle sheath 426 will be attached to the guide tip 406 of guide body 402. The central lumen of the needle sheath 426 receives a support holster 428 attached to the distal end of the needle shaft 404, as well as the needles 410. As with previous embodiments, the butts of the needles 410 are removably received within the support holster 428. The sheath 426 will be sufficiently long to permit the needles to extend at least 5 cm beyond the distal end of guide body 402.
Prior to use, the suture applying device 400 will be in the configuration illustrated in
After the guide tip 406 has been passed through the puncture site to be sutured, the needles may then be drawn proximally forward through the tissue to be sutured by drawing proximally on handle 430 at the proximal end of needle shaft 404. The method of the present invention will now be described in more detail with reference to
The situation following an interventional or other vascular procedure, where the attending physician is satisfied that the puncture site may be sealed, is illustrated in
Procedures requiring access to the vessel are performed at this time, e.g., insertion of medical devices typically involving the use of catheters, sometimes referred to as the pre-close technique. For example, following suture positioning, stent graft insertion may be performed through the access point in the blood vessel. A heart valve replacement, such as the SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine, Calif., USA), may be deployed through this access point. Such procedures may include introducer sheaths having an outer dimension of 5 F-8 F, and may be larger than 8 F, as discussed below.
Following withdrawal of the catheters and/or other medical devices, the suture can then be tied and the knot pushed back down through the support sheath 440. The knot will then only be tightened when the needle sheath is finally withdrawn from the puncture site A.
It can be seen that the guide tip 406 deflects the needles radially outward so that the pattern of four needles engages the artery wall in an approximately square pattern about the arteriotomy A. After the sutures are tied and the knots advanced back through the support sheath 440, the resulting pattern of tied suture will appear as in
Device 400 has certain advantages over the previous embodiments. Since it is not necessary to capture the needles using an internal capture mechanism, the needles need not have barbs. Such barbless needles will minimize trauma to the arterial tissue around the puncture site A and simplify the procedure. The guide body 402 and guide tip 406 are designed as an integral structure to assure that needles 410 will be precisely centered around the puncture site A, and will very reliably enter the needle lumens 420 in guide body 402. Also, tip 406 will occlude the arteriotomy puncture during the performance of the procedure, providing hemostasis. Moreover, the entire procedure is simplified, with fewer discrete steps being performed. The user need only introduce the device over-the-wire and thereafter draw out the needle shaft to carry the needles through the tissue to be sutured and outward through the guide body, where the suture becomes accessible and may be tied in a conventional manner.
The present invention offers surgeons an automated method for delivering a pre-tied knot to an incision formed in a lumen. The present invention minimizes the problems associated with a surgeon manually delivering a knot to an incision site. Thus, the present invention reduces the time required to accurately and precisely place a suture knot in close proximity to an incision formed in a lumen, thereby decreasing both the overall time a patient spends in surgery and the costs associated with spending time in surgery.
A clinical trial was performed, which was a prospective, multicenter, randomized, concurrently-controlled trial. Patients with AAA who were suitable candidates for endovascular repair using a graft introduction system and for percutaneous femoral artery closure and who met the prospectively defined inclusion/exclusion criteria were randomized to treatment with a graft system via a totally percutaneous access approach (PEVAR=Test) or via a standard vascular exposure cutdown approach (SEVAR=Control). PEVAR patients had their femoral artery access sites closed using, e.g., the Perclose ProGlide® suture-mediated closure system (“ProGlide”) (Abbott Vascular, Inc., Redwood City, Calif.), substantially identical to the vessel closure device 10 described herein. Prior to the randomization of the first patient at each investigational site, a minimum of two patients were treated in a roll-in phase at the investigational site. Roll-in patients underwent the same treatment and follow-up as the randomized patients.
The PEVAR trial includes the Independent Access Site Closure Study which is a set of analyses designed to evaluate the safety and effectiveness of the vessel closure device using the pre-close technique to percutaneously close ipsilateral femoral artery access sites up to 21 F sheath size. The primary analysis is based on a non-inferiority hypothesis test to demonstrate the vessel closure arm is non-inferior to the SEVAR arm. Data from the ProGlide (n=50) and SEVAR (n=50) arms, are described herein.
Methods: All patients underwent pre-procedure assessments prior to enrollment in the trial. The protocol requires clinical assessments prior to discharge, at one month and six months. An independent clinical events committee adjudicated potential endpoint events of both major and minor ipsilateral access site vascular complications. The enrollment has been completed and follow-up will continue until all patients complete the six-month visit. The following assessments were required at pre-discharge, one month, and six months:
Medication review (one and six months only); physical exam, including overall health and physical assessment, lower extremity sensorimotor exam and access site assessment; serum creatinine, blood urea nitrogen, hematocrit and hemoglobin; ABI; contrast-enhanced CT scan of the abdomen and pelvis (one month only); bilateral femoral duplex ultrasound (pre-discharge and six month only); SF-36 QOL (1 and 6 months only); pain scale; and adverse events.
Patient Demographics: In general, baseline demographics were comparable between the ProGlide and the SEVAR patients. There was a difference in age between the ProGlide and SEVAR arms (69.9±6.6 vs. 73.2±8.8) that did not appear to affect the overall study outcome, based on additional adjusted analysis.
Primary Endpoint: The primary endpoint for the trial is the major ipsilateral access site vascular complication rate at 30 days for patients treated percutaneously (PEVAR ProGlide arm) compared to that of patients treated using standard surgical vascular access (SEVAR group).
Major ipsilateral access site vascular complications are a composite of the following events: access site vascular injury requiring surgical repair, angioplasty, or ultrasound-guided compression, or thrombin injection; new onset lower extremity ischemia that is attributed to arterial access or closure causing a threat to the viability of the limb and requiring surgical or additional percutaneous intervention; access site-related bleeding requiring transfusion; access site-related infection requiring intravenous antibiotics or a prolonged hospitalization; access site-related nerve injury that is permanent or requires surgery.
The study results show that at 30 days, ProGlide patients had a 6.0% (3/50) major ipsilateral access site vascular complication rate vs. the SEVAR patients who had a 10% (5/50) major ipsilateral access site vascular complication rate. The non-inferiority test for the primary endpoint revealed a p value=0.0048 and resulted in the rejection of the null hypothesis, demonstrating that ProGlide is non-inferior to SEVAR in the closure of femoral artery access sites up to 21 F sheath size (Table 1).
Table 1 represents the results of a non-inferiority test for primary endpoint-per subject analysis for a modified intent-to-treat population (defined as all patients who were randomized and treated) for ProGlide vs. SEVAR. The 95% confidence interval was the Clopper-Pearson exact confidence interval. The p-value represents a one-sided p-value and 95% confidence interval for non-inferiority test by using asymptotic test statistics with non-inferiority margin of 10%.
Select Secondary Endpoints: In the trial, the following select secondary endpoints were also evaluated:
Procedure time was defined as elapsed time from the first skin break to final closure (skin to skin time).
Minor ipsilateral access site complications included minor ipsilateral access site vascular complications and narcotic analgesic use for ipsilateral access site pain at 30 days.
Minor ipsilateral access site vascular complications included: Access site pseudoaneurysm or AV fistula documented by ultrasound; Access site hematoma ≧6 cm; Post-discharge access site-related bleeding requiring >30 minutes to re-achieve hemostasis; Lower extremity arterial emboli or stenosis that is attributed to arterial access or closure; Deep vein thrombosis; Access site-related vessel laceration; Transient access site-related nerve injury; Access site wound dehiscence; Access site related lymphocele; and Localized access site infection treated with intramuscular or oral antibiotics.
Additional secondary endpoints considered include: time to actual hospital discharge defined as elapsed time from sheath removal to actual physical discharge from the hospital; time to ambulation defined as elapsed time between sheath removal and time when the patient stands and walks at least 20 feet without re-bleeding; ipsilateral pain score at pre-discharge; time to hemostasis for the ipsilateral access site defined as elapsed time from sheath removal to first observed cessation of CFA bleeding (excluding cutaneous or subcutaneous oozing); closure device success defined as successful achievement of index procedure ipsilateral access site hemostasis with percutaneous closure without surgical intervention; and ipsilateral access site closure success defined as successful achievement of hemostasis with percutaneous closure devices and without surgical intervention and freedom from major ipsilateral access site vascular complications within 48 hours of the index procedure or hospital discharge, whichever occurs first.
As shown in Table 2, the ProGlide arm had a 25% shorter procedure time than the SEVAR arm (106.5±44.9 vs. 141.1±73.4, p=0.0076). Although there were no statistically significant differences in the minor ipsilateral access site complications, time to actual hospital discharge, time to ambulation and ipsilateral pain score at pre-discharge between the ProGlide and SEVAR arms, fewer patients in the ProGlide arm required narcotic analgesic use, had minor ipsilateral access site complications and ProGlide patients had slightly shorter time to actual discharge. In the ProGlide arm, the time to hemostasis for the ipsilateral access site was 57% shorter than in the SEVAR arm (9.8±17 vs, 22.7±22.9 minutes, 95% CI of the difference [−21.1, −4.7]). In addition, the ProGlide arm achieved a high device success rate and high access site closure success rate at 96% and 94%, respectively.
The 95% Confidence Interval for Procedure Time, Time to Actual Hospital Discharge, Time to Ambulation, Ipsilateral Pain Scale Score at Pre-Discharge, and Difference (95% CI) were determined by normal approximation. The 95% Confidence Interval for Minor Ipsilateral Access Site Complications at 30 days, Minor Ipsilateral Access Site Vascular Complications at 30 days, Narcotic Analgesic Use for Ipsilateral Access Site Pain at 30 days, Time to Hemostasis for Ipsilateral Access Site, Closure Device Success, and Access Site Closure Success were determined by Clopper-Pearson exact confidence interval. The Superiority Test p-value for the for procedure time and the Time to Hemostasis for Ipsilateral Access Site was determined by two-sample t-test, pre-specified hypothesis test based hierarchical test procedure. The Superiority Test p-value for the Minor Ipsilateral Access Site Complications at 30 days was determined by Fisher's Exact Test, pre-specified hypothesis test based hierarchical test procedure. The Minor Ipsilateral Access Site Complications at 30 days was a composite endpoint including minor Ipsilateral Access site vascular complications and narcotic analgesic use for Ipsilateral access site pain at 30 days. For the Difference (95% CI) of the Minor Ipsilateral Access Site Complications at 30 days, there was an insufficient sample size or small frequency in the numerator for the validity of normal approximation assumption
Adverse events related to major and minor ipsilateral access site vascular complications that occurred within the first 30 days are listed in Table 3, which includes only the subject's first occurrence of each event.
Clinical Data from the Roll-in Phase: There were 22 patients treated in the ProGlide roll-in phase of the PEVAR trial. The mean age of this treatment group was 71.1±6.9 years. The major ipsilateral access site vascular complication rate was 4.5% (1/22). The mean procedure time was 118.2±43.4 minutes, and the average time to hemostasis was 7.7±6.8 minutes for the roll-in phase. Additionally, the device success rate and the access site closure success rate were both 95.5% respectively. These results are comparable to the ProGlide arm in the randomized phase and substantiate the safety and effectiveness of the ProGlide devices.
The Closer IDE clinical trial was designed as an equivalency trial for the 30-day primary combined safety endpoint of freedom from major complications and a primary efficacy endpoint of time to discharge when compared to the control group (STAND II Trial). The study prospectively examined the safety and effectiveness of femoral artery closure using the Closer 6 F SMC Device, substantially identical to the vessel closure device 10, 10′, 100 and 300 described herein, following interventional catheterization procedures using 5 F to 8 F sheaths. Two hundred twenty five (225) patients were enrolled in post-close arm and one hundred sixty (160) patients were enrolled in the pre-close arm of the Closer IDE Trial. In the post-close arm, the deployment of the Closer device occurred at the end of the catheterization procedure. In the pre-close arm, the Closer device was deployed in two steps with suture delivery at the beginning of the catheterization procedure with knot tying and knot delivery occurring at the end of the procedure.
Procedural success was achieved in 223 patients (99.1%) in the post-close arm and 158 patients (98.8%) in the pre-close arm. Time to discharge was 28.9±22.7 hours and 30.1±33.9 hours for the post-close and pre-close patients respectively. The secondary endpoint of time to hemostasis was 10.9±42.0 minutes and 8.2±51.0 minutes for the post-close and pre-close patients respectively, versus 7.9±6.4 hours for the control group patients, p<0.0001, and the secondary endpoint of time to ambulation was 4.7±7.1 hours and 6.5±11.4 hours for the post-close and pre-close patients respectively.
Device success was 92.0% (207/225 patients) in the post-close arm and 89.4% (143/160 patients) in the pre-close arm. Failure to deploy the Closer occurred in 17 (7.6%) patients in the post-close arm and 15 (9.4%) patients in the pre-close arm.
A major complication was defined as surgical repair of vascular injury, ultrasound-guided compression, groin related transfusion, or groin related infection requiring IV antibiotics and extended hospitalization. The primary safety endpoint was the combined rate of major complications at 30 days. For the post-close arm, one patient received a blood transfusion subsequent to a retroperitoneal bleed. Another patient underwent surgical repair of a vascular injury and received a blood transfusion subsequent to the intervention. Both patients were free of symptoms at time of follow up. For the pre-close arm, one patient developed a hematoma >6 cm as a result of insufficient hemostasis. Subsequently, the patient required vascular surgery to repair the femoral artery and received blood transfusions intraoperatively. The second patient received IV antibiotic therapy for a local infection that presented post discharge. Both patients reported no further sequelae at time of follow-up.
The incidence of vascular complication other than major was a secondary safety endpoint of the study and in the post-close arm consisted of one (0.4%) false aneurysm, one (0.4%) infection requiring IM and PO antibiotics, two (0.9%)>6 cm hematomas, and two (0.9%) retroperitoneal bleeds not requiring intervention. For the pre-close arm, the incidence of vascular complication other than major consisted of one (0.6%)>6 cm hematoma and one (0.6%) groin infection requiring PO antibiotics. All patients were free of symptoms at time of follow up. The results of the effectiveness measures are summarized in Table 4.
The number of patients listed under effectiveness measures is less than the total patients studied due to missing data for some patients. Device success is defined as acute success using the device only or the device+adjunctive (non-arterial) compression.
Thus, the vessel closure system reduced the time to hemostasis, ambulation (10 feet) and discharge in patients who had undergone diagnostic or interventional catheterization procedures without complicating clinical conditions.
ADVERSE EVENTS: The Closer IDE Trial was designed as a multi-center, multi-operator, prospective registry enrolling patients in a post-close arm and a pre-close arm. The post-close arm studied the use of a 6 F system following interventional procedures using 5 F to 6 F sheaths. The pre-close arm studied the use of the 6 F system following interventional procedures using 7 F to 8 F sheaths utilizing the pre-close technique. The pre-specified analysis of the primary safety endpoint of the IDE Trial was the incidence of the combined rate of major complications at 30 days of patients undergoing interventional catheterization procedures. Post treatment, ultrasound evaluations were performed 0 to 15 days post discharge to verify detection of clinical complications. Two major complications were reported in each of the post-close and pre-close arms of the trial. Neither of the two major complications reported in the post-close or pre-close arms were considered unanticipated events. No delayed major hemorrhagic events were reported despite early ambulation and early discharge of the patients with the closure device. The adverse events that were observed during the trial are reported in Table 4.
No groin or device related deaths were reported in the trial among the post-close or pre-close study patients. Other adverse events potentially associated with the use of the closure system were reported as an underlying event or did not occur during the clinical study. These include: deep vein thrombosis, infection extending hospitalization, late bleeding, wound dehiscence, vessel laceration, local pulse deficits or ischemia, embolization, transitory local irritation, nerve injury and vascular spasm. In addition, polyester surgical sutures elicit a minimal acute inflammatory reaction in tissues, followed by gradual encapsulation of the suture by fibrous connective tissue. Polyester surgical sutures are not absorbed, nor is any significant change in tensile strength known to occur in vivo.
The following describes the techniques used herein:
Arterial Site and Puncture Considerations: Before inserting the access needle, ultrasound guidance can be used to visualize the common femoral artery or fluoroscopy can be used to visualize the femoral head. When using the femoral head as a reference point, the middle of the femoral head is targeted as the puncture site. A femoral angiogram through the introducer sheath (or procedural sheath) can be performed to verify that the access site is in the common femoral artery before anticoagulants are given. The anterior wall of the common femoral artery can be punctured at an angle of approximately 45 degrees, avoiding side wall or posterior wall femoral artery punctures.
Prior to deployment of the vessel closure device, a femoral angiogram can be performed to evaluate the femoral artery site for vessel size, calcium deposits, tortuosity, and for disease or dissections of the arterial wall to avoid device cuff misses (device needles not engaging with the cuffs) and/or posterior wall suture placement and possible ligation of the anterior and posterior walls of the femoral artery. Angiographically verification can be performed to ensure that the puncture is on the anterior wall of the common femoral artery. The puncture should be proximal to the bifurcation of the superficial femoral artery and the profunda femoris branch and distal to the inferior margin of the inferior epigastric artery.
Deployment sequence to close the access site of a catheterization procedure performed through a 5 F to 8 F sheath size: In some embodiments, a 0.038″ (or smaller) guidewire GW is placed through the procedural (or introducer) sheath. The procedural sheath is removed while applying pressure on the groin to maintain hemostasis. The vessel closure device is backloaded over the guidewire until the guidewire exit port of the device sheath is just above the skin line. The guidewire is removed before the exit port crosses the skin line. The vessel closure device is further advanced just until brisk pulsatile flow of blood is evident from the marker lumen. The device is then positioned at a 45-degree angle. The foot is deployed by lifting the lever on top of the handle only if brisk pulsatile flow of blood (“mark”) is evident from the marker lumen.
The vessel closure device is then gently pulled back to position the foot against the arterial wall. If proper position of the foot has been achieved, tactile sensation will be felt and blood marking will cease or be significantly reduced to a slight drip. If marking does not stop or significantly change, the angiogram can be evaluated for femoral artery size, calcium deposits, tortuosity, disease and for location of the puncture (ensure footplate is not in bifurcation or side branch). The device can be repositioned to stop blood marking, the wire can be reinserted, the device can be removed to hold manual compression, a new sheath can be inserted.
While maintaining vessel closure device position, it is stabilized with the operator's free hand (the one not used to deploy the device) to maintain the gentle retraction and to ensure the vessel closure device does not twist or move forward during deployment. The operator's other hand is used to deploy needles by pushing on the plunger assembly until contact of the collar of the plunger with the proximal end of the body is visually confirmed.
Using the operator's thumb as a fulcrum on the handle, the needles can be gently disengaged by pulling the plunger assembly back and completely removing the plunger and needles from the body of the vessel closure device. One suture limb will be attached to the anterior needle. The posterior needle will be free of suture. The plunger should be pulled back until the suture is taut, which confirms that all the suture as been fully refracted from the body of the device.
A suture-trimming mechanism located on the handle can be used to cut the suture from the anterior needle distal of the link. The device can the be relaxed, and the foot returned to its original position by pushing the lever down to the body of the device. The vessel closure device is withdrawn until the guidewire port exits the skin line.
The suture adjacent to the device sheath is grasped, and the suture ends are pulled through the distal end of the proximal guide. The rail suture limb is the longer of the two suture limbs, and is used to advance the knot. The shorter, non-rail suture limb is used to lock the knot.
If the operator chooses to maintain wire access, the guidewire is reinserted after exposing the guidewire port at skin level and after the sutures have been harvested from the distal guide but before removing the device for knot advancement. The following steps are performed when closing over the wire:
There should be sufficient guidewire exposed out of the guidewire exit port before removing the device. The rail limb of suture should be wrapped around he operator's left index finger, low close to skin level. The vessel closure device is removed with the right hand, while maintaining an adequate length of guidewire inside the artery. This allows placement of another vessel closure device or a sheath in the event that hemostasis is not obtained.
While removing the device with the right hand, the operator simultaneously advances the knot to the arteriotomy by applying slow, consistent increasing tension to the rail suture limb, keeping the suture coaxial to the tissue tract.
If bleeding is controlled, the operator can then remove the guidewire. Next, a snared knot pusher or a suture trimmer is used, as described below, to advance and tighten the knot until complete closure is achieved. The security of the knot can be confirmed by having the patient cough and/or bend his/her leg. Additionally, patients may be able to move freely in bed without head of bed or leg restrictions if the close is successful.
The suture can be placed around the arteriotomy at the beginning of the procedure and knot advancement can be placed on hold until the procedure is complete. The steps described below are performed when using the pre-close technique:
After completing the step of withdrawing the vessel closure device until the guidewire port exits the skin line described above, the device is slightly rotated until the operator can see the two suture limbs in the bend of the distal guide. The sutures are grasped adjacent to the sheath. While holding the two suture limbs together, both suture ends are pulled through the distal end of the proximal guide.
A shodded hemostat or clamp can be placed to hold the two suture limbs together at the distal end of the non-rail suture limb (shortest limb). To prevent knot advancement or locking of the knot, care must be taken not to pull on the individual suture limbs until the clamp is securely holding the two limbs together. After securing the suture limbs and before inserting the procedural sheath, the clamp can be pulled until the suture is taut to remove any suture slack from the tissue tract.
Procedures requiring access to the vessel are performed at this time, e.g., insertion of medical devices typically involving the use of catheters. For example, stent graft insertion may be performed through the access point in the blood vessel. A heart valve replacement, such as the SAPIEN transcatheter heart valve (Edwards Lifesciences, Irvine, Calif., USA), may be deployed through this access point. Such procedures may include introducer sheaths having an outer dimension of 5 F-8 F, and may be larger than 8 F, as discussed below.
At the end of the catheterization, the guidewire can be reinserted into the procedural sheath. Knot advancement to close the arteriotomy will resume starting with the steps for closing over the wire.
Knot Advancement:
In one embodiment, a snared knot pusher 600 (see
The rail suture limb (longer limb) is securely wrapped around the operator's left forefinger, low close to skin level. The suture should not be tightened around the sheath. The device or the arterial sheath (if the device was deployed at the beginning of the catheterization procedure) is removed from the artery, while simultaneously pulling gently on the rail limb. The suture is maintained coaxial to the tissue tract. With the rail suture limb securely wrapped around the operator's left forefinger, and held coaxial to the tissue tract, the suture limb can be pulled with slow, consistent increasing tension while advancing the knot pusher into the tissue tract with the operator's right hand until the knot reaches the arterial surface.
The knot pusher can be placed under the operator's left thumb to assume a single-handed position and to complete knot advancement by slow, consist increasing tension on the left forefinger until the rail suture is taut (guitar string tightness).
With the knot pusher held in position and tension maintained on the rail limb, the knot is tightened by gently pulling on the non-rail (shorter) suture limb keeping it coaxial to the tissue tract.
Hemostasis of the access site is achieved when the knot is fully advanced to the arterial surface, the slack is gently pulled from the knot with the non-rail limb while the knot pusher holds tension on the rail limb of the suture, and the tissue is in complete apposition.
The knot pusher can then be removed from the tissue tract, tension relaxed on the suture, and testing for hemostasis performed by having the patient cough or bend his/her leg.
The security of the knot can be confirmed by having the patient cough and/or bend his/her leg. Using the suture trimmer 610 (described below) or a new, sterile scalpel or scissor, the trailing suture limbs can be cut below the skin. Additionally, patients may be able to move freely in bed without head of bed or leg restrictions if the close is successful. If hemostasis cannot be achieved, apply manual compression until hemostasis is achieved.
In one embodiment, the suture trimmer 610 (see
The suture should not be tightened around the sheath. The vessel closure device or the arterial sheath (if the vessel closure device was deployed at the beginning of the catheterization procedure) is removed from the artery, while simultaneously pulling gently on the rail limb. The suture is maintained coaxial to the tissue tract.
With the rail (longer) suture limb securely wrapped around the operator's left forefinger, the rail limb is placed into the suture trimmer 610 utilizing the following steps: the thumb knob 614 on the suture trimmer is retracted with the operator's right hand. The suture trimmer is placed under the suture limb making an “x” or a “cross” between the suture limb and the mid-point of the suture trimmer. The operator slides the suture trimmer back to load the suture into the suture gate 612 located at the distal end of the suture trimmer. Keeping the thumb knob 614 retracted, the suture trimmer is turned coaxial to the suture and then the thumb knob 614 is released to capture the suture in the suture gate 612. Once the suture is loaded correctly, the suture trimmer should slide easily within the suture trimmer.
With the suture limb and suture trimmer coaxial to the tissue tract, the knot can be moved to the arterial surface by advancing the suture trimmer with the operator's right hand while placing slow, consistent increasing tension on the rail suture with the left forefinger. The suture trimmer and suture limbs should always remain coaxial to the tissue tract. The thumb knob should be at 12 o'clock (facing the ceiling), and the suture trimmer should not be rotated during advancement.
With the rail (longer) suture limb securely wrapped around the left forefinger, the suture trimmer is placed under the left thumb of the operator to assume a single-handed position and complete knot advancement with slow, consistent increasing tension until the suture is taut (guitar string tightness).
With the suture trimmer in place and the suture taut, the knot can be tightened by gently pulling the non-rail (shorter) suture limb, keeping it coaxial to the tissue tract.
Hemostasis of the access site can be achieved when the knot is fully advanced to the arterial surface, the slack is gently pulled from the knot with the non-rail limb while the suture trimmer holds tension on the rail limb of the suture, and the tissue is in apposition.
The suture trimmer can then be removed from the tissue tract, relaxing tension on the suture, and testing for hemostasis by having the patient cough or bend his/her leg. If hemostasis has not been achieved, the single-handed position can be continued for 20 seconds, or until hemostasis is achieved. The knot can be secured again by gently pulling on the non-rail suture limb. The security of the knot can be confirmed by having the patient cough and/or bend his/her leg. Additionally, patients may be able to move freely in bed without head of bed or leg restrictions if the close is successful.
Once hemostasis is achieved, the suture trimmer is used to trim the sutures below the skin. While holding both suture limbs together and pulled taut, both suture limbs are loaded into the suture trimmer as described above and the suture trimmer is advanced to the arterial surface. The sutures are trimmed by pulling back on the trimming lever 616. The operator maintains the trimming lever pulled back while removing the suture trimmer and trimmed suture limbs from the tissue tract. If only one suture limb has been loaded and trimmed, the same technique is repeated on the other suture limb. If hemostasis cannot be achieved, manual compression can be applied until hemostasis is achieved.
The following instructions describe the deployment sequence for closing the access site of an interventional catheterization procedure performed through 8.5 F to 21 F sheath size. The pre-close technique using at least two devices is used when closing sheath sizes from 8.5 F to 21 F.
In some embodiments, a 0.038″ (or smaller) guidewire GW is advanced through the access point through an introducer sheath. The guidewire is advanced to location distal (downstream) from the affected site, e.g., AAA. The introducer sheath is removed while applying pressure on the groin to maintain hemostasis. The first of two vessel closure devices is backloaded over the guidewire until the guidewire exit port of the device sheath is just above the skin line. The guidewire is removed before the exit port crosses the skin line. The vessel closure device is advanced into the blood vessel just until brisk pulsatile flow of blood is evident from the marker lumen. The device lever is positioned facing the ceiling (12 o'clock).
The first vessel closure device is rotated approximately 30 degrees towards the patient's right side (approximately 10 o'clock). The device is positioned at a 45-degree angle to the arterial lumen (see, e.g.,
The device is gently pulled back to position the foot against the arterial wall. If proper position of the foot has been achieved, a tactile sensation will be felt by the operator, and blood marking will cease or be significantly reduced to a slight drip. If marking does not stop or significantly change, the angiogram can be evaluated for femoral artery size, calcium deposits, tortuosity, disease and for location of the puncture (e.g., ensuring the footplate is not in bifurcation or a branch vessel of the common femoral artery). The device is repositioned to stop blood marking (maintaining the 30 degree rotation), or the wire reinserted and the situation evaluated before continuing the procedure.
While maintaining the device position, the operator can stabilize the device with the free hand (e.g., the one not used to deploy the device) to maintain gentle retraction and to ensure the device doesn't twist or move forward during deployment. The operator's other hand is used to deploy the needles by pushing on the plunger assembly until visually confirmation that the collar of the plunger is making contact with the proximal end of the body. (See, e.g.,
Using the operator's thumb as a fulcrum on the handle, the needles can be disengaged by pulling the plunger assembly back and completely removing the plunger and needles from the body of the device. One suture limb will be attached to the anterior needle. The posterior needle will be free of suture. The operator can then pull back on the plunger until the suture is taut, which confirms that the suture has been fully refracted from the body of the device. (See, e.g.,
The suture-trimming mechanism located on the handle of the device can be used to cut the suture from the anterior needle distal of the link. Use of a new, sterile scalpel or scissors can be used alternatively.
The device can be relaxed, and the foot is returned to its original position by pushing the lever on top of the device, down to its original position. (See, e.g.,
The first vessel closure device is withdrawn from the patient until the guidewire port exits the skin line. The device is slightly rotated until the operator can see the two suture limbs in the bend of the distal guide. The sutures are then grasped adjacent to the sheath. While holding the two suture limbs together, both suture ends are pulled through the distal end of the proximal guide.
A shodded hemostat or clamp can be placed to hold the two suture limbs together at the distal end of the non-rail suture limb (shortest limb). To prevent knot advancement or locking of the knot, care must be taken not to pull on the individual sutures until the clamp is securely holding the two suture limbs together.
The clamp is then gently pulled until the suture is taut to remove any suture slack from the tissue tract. The clamped suture is placed on the right side of the patient under a sterile towel. It is important to identify which suture is deployed first, as this is the knot that needs to be advanced first at the end of the procedure.
The guidewire GW is the reinserted. There should be sufficient guidewire inside the vessel and exposed out of the guidewire exit port for device exchange.
The first vessel closure device is removed, while holding compression above the puncture site and maintaining an adequate length of guidewire inside the artery. This allows placement of a second vessel closure device.
The steps described above are then repeated with the second vessel closure device (i.e., the step of loading the second vessel closure device and its introducer sheath over the guidewire through the step of placing a shodded hemostat or clamp to hold the suture limbs together). As discussed above, the first device was rotated approximately 30 degrees towards the patient's right side (approximately 10 o'clock), the second vessel closure device should be rotated approximately 30 degrees towards the patient's left side (approximately 2 o'clock). As illustrated in
The operator then removes excess suture slack from the tissue track, and places the clamped suture for the second device on the left side of the patient under a sterile towel. It is important to identify which suture was placed first and which suture was placed second. At the completion of the procedure, the suture knots will be advanced in the order they were placed. The knot 35a from the first device placed on the right side (10 o'clock) of the patient would be advanced, followed by the knot 35b from the second device placed on the left side (2 o'clock) of the patient. Knot advancement will be placed on hold at this point, and the sutures set aside under sterile towels while the operator proceeds with the procedure.
When utilizing a pre-close technique, the vessel closure device is exchanged for an appropriately sized introducer sheath. A medical device such as a stent graft or replacement heart valve is inserted into the vessel to the site of the AAA prior to securing the sutures to close the access point, as discussed below.
After completing the procedure, a hydrophilic or general purpose guidewire is advanced into the artery. An adequate length of guidewire is maintained in both the vessel and exposed out the guidewire exit port to ensure guidewire access is maintained until hemostasis is achieved. The secured sutures are then irrigated with heparinized saline to remove any dry blood. The clamp is removed from the first suture (patient's right side (10 o'clock)).
The rail portion or limb of the suture is the longer of the two suture portions or limbs. This rail suture limb is used to advance the knot. The shorter, non-rail suture limb is used to lock the knot. The rail suture limb securely wrapped around the operator's left forefinger, low close to skin level, and the suture is held coaxial to the tissue tract. While maintaining guidewire access, the entire sheath system is removed and the rail limb is simultaneously pulled with slow, consistent increasing tension. Manual pressure is applied proximal to the puncture site for hemostasis, while the sheath is removed and during initial suture advancement.
The knot is not locked at this point. Due to the size of the arteriotomy, use of the snared knot pusher or suture trimmer discussed above may be needed to approximate the tissue edges. However, the knot is not locked or excessively tightened while the guidewire is still in the vessel. The suture limbs of the first suture are placed on the right side of the patient for easy identification as the first suture deployed.
The clamp is removed from the second suture (patient's left side (2 o'clock)) and the knot is advanced using the same technique, maintaining guidewire access. Again, the know of the second suture is not locked. The suture limbs of the second suture are placed on the left side of the patient for easy identification as the second suture.
The site is then assessed for hemostasis. If brisk bleeding is observed, the first suture (patient's right side (10 o'clock)) is advanced again, and the second suture (patient's left side (2 o'clock)) is advanced again. Multiple knot advancements can be performed when closing larger sheath sizes. However, the knot is not locked or excessively tightened while the guidewire is still in the vessel. Until the wire is removed, some bleeding may be visible, but it should not be pulsatile blood flow.
If acceptable hemostasis is not observed, additional vessel closure devices can be deployed at this point. The steps above are repeated (i.e., the step of backloading the device over the guidewire through the step of withdrawing the device until the guidewire port exits the skin line) with the next vessel closure device. However, in some embodiments, the third device is not rotated. Instead, the device will be deployed in a straight cranial/caudad position (12 o'clock) in order to deploy suture 34c as illustrated in
The site is assessed again for adequate hemostasis. If bleeding is controlled, the operator should then remove the guidewire. With the rail suture limb (longer limb) securely wrapped around the left forefinger of the operator, the first suture (patient's right side (10 o'clock)) is advanced, and then the suture trimmer or snared knot pusher is placed under the left thumb to assume a single-handed position and complete knot advancement with slow, consistent increasing tension until the suture is taut (guitar string tightness). With the suture trimmer or snared knot pusher in place and the suture taut, the knot is tightened by gently pulling the non-rail (shorter) suture limb keeping it coaxial to the tissue tract.
The suture is not yet cut. The same steps are followed to advance the second suture (patient's left side (2 o'clock)), coaxial to the tissue tract and lock the knot, but the suture is not cut. If applicable, the additional sutures are advanced, and the knots are locked in the order that they were placed (e.g., 10 o'clock, 2 o'clock, 12 o'clock), and bleeding is assessed. If hemostasis is deemed adequate, then the suture tails are cut below the surface of the skin using the suture trimmer, discussed above, or a new, sterile scalpel or scissors.
Apply an appropriate dressing to the access site. Assess the access site as per hospital standard of care. Patients who have undergone a diagnostic or interventional procedure using 5-8 F sheaths may be ambulated two hours after the vessel closure device procedures. For patients who have undergone an interventional catheterization procedure using 8.5-21 F sheaths, post-procedure ambulation and patient care is at the discretion of the physician. In determining whether to ambulate or discharge an individual patient, all clinical factors are considered, including but not limited to, anticoagulation regimen, antiplatelet and thrombolytic agents administered, oozing or bleeding from the access site, venous access site hemostasis, the general cardiovascular condition of the patient, anesthetic levels, and the overall clinical condition of the patient.
In one embodiment, the closure devices 10, 10′, 100, 300, and 400 described herein are used for closure of a patient's vein.
In another embodiment, the closure devices described herein include a coated suture. In one embodiment, the suture 34 is coated with a hydrogel 39a. (
In another embodiment, the closure devices described include a collagen suture 34′. Such suture is resorbable by the body. (
As described hereinabove and illustrated in FIGS. 5 and 29A-B, two or more needles are deployed from the closure device to pierce the wall of the vessel at two or more locations. Such needles carry and position a suture through the wall of the vessel. Such sutures are subsequently withdrawn to close the vessel opening. During deployment, the needles can be radially outwardly (laterally) deflected in order to achieve the desired spread, e.g., such that the separation of the two or more needles spans the opening created in the vessel. For example, as illustrated in
In a further embodiment, the closure devices described herein are provided with the feature of selectively adjustable spacing of the needles for positioning sutures through a wall of a vessel in connection with the closure of vessel openings which vary in size, e.g., from about 8 Fr to about 24 Fr. This feature permits the surgeon to select the “spread” of the needles, e.g., the distance between the needle tips, during the procedure, as required by the size of the particular vessel opening being closed. For example, it is desirable in certain procedures to produce an opening in the vessel of about 8 Fr. In other procedures, the opening in the vessel may be as large as 24 Fr in order to accommodate larger apparatus, such as expandable grafts. Thus, vessel openings of different sizes can be closed with the use of single vessel closure device.
As illustrated in
In some embodiments, the needles 510 are fabricated from a material having flexible and/or resilient characteristics, and can be fabricated from a shape memory alloy, such as nitinol. As illustrated in
Without limiting the above disclosure, the mechanism illustrated in
As was generally described above, foot 24′ includes needle receptacles 52′ adjacent the ends of the foot. A fitting 40′ (with an associated end of suture 34′) is disposed within each needle receptacle, and a surface of the receptacle tapers proximally and outwardly so as to guide the advancing needles 38′ into engagement with fittings 40′ when foot 24′ is in the deployed position. As fittings 40′ (and associated portions of suture 34′) are releasably supported in the foot, needles 38′ can be withdrawn proximally so as to draw the fittings and suture ends from the foot proximally into (and optionally through) shaft 12′.
In some embodiments, foot 24′ includes features in order to accommodate the variable spread of the needles 38′. For example, foot 24′ can incorporate a center component 25′ and two outer components 27′ and 29′ which are slidable (or otherwise movable) with respect to the center component 25′ via springs 31.′ In this manner, outer components 27′ and 29′ (and corresponding receptacles 52′) can be maintained in a first position as shown in
The device 400′ comprises a guide body 402′ and a needle shaft 404′. The guide body 402′ includes a guide tip 406′ at its distal end, which guide tip includes a plurality of guide channels to receive the proximal ends of needles 410′. The needles 410′ as illustrated comprise a sharpened tip section 412′ and an elongate shank portion 414′, but may also be manufactured as an integral piece. Needles 410′ are fabricated in the same manner as needle 510 and 38′ discussed above, e.g., having a pre-formed bent configuration to allow for a selectively adjustable spread between the needle tips 412′. The shank portion 414′ will be sufficiently long so that the needles may be pushed from their butt end by a support holster 428 (illustrated in
The guide body 402 further includes a plurality of needle lumens 420′ which are axially aligned and spaced about the periphery of the guide body. The needles 410′ will enter the distal ends of the lumens 420′ as the needles are advanced proximally relative to the guide body.
A flexible needle sheath 429′ is slidable over the needle shaft 404′. Prior to use, the sheath 429′ will cover a first portion of the needles 410′. That is, the needles will define a first spread configuration. As the sheath is retracted from the needles (in the direction illustrated by arrows denoted 450′), the needles are permitted to resume their pre-bent configuration, thereby defining a greater spread between needle tip 412′ as illustrated in
As illustrated in
A further embodiment of an anchor for securing a suture deployed, e.g., through a hypotube or catheter, is illustrated in
In another embodiment illustrated in
A further embodiment of an anchor for securing a suture deployed through an introducer, e.g., a hypotube or catheter, is illustrated in
According to a further embodiment illustrated in
Because of the shape memory properties, the resilient strip 1004 can be straightened and stored inside a lumen of the hypotube 1010 (
While particular embodiments of the invention have been herein described in detail, it is to be appreciated that the present invention encompasses variations and combinations thereof, as may be apparent to one of ordinary skill from this disclosure. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
This application is a continuation-in-part of U.S. patent application Ser. No. 13/112,618, titled, CLOSURE DEVICES AND METHODS, filed May 20, 2011, which is a continuation-in-part of U.S. patent application Ser. No. 12/684,470, titled CLOSURE DEVICES, SYSTEMS, AND METHODS, filed Jan. 8, 2010, which claims the benefit of U.S. Provisional Application No. 61/143,751, titled VESSEL CLOSURE DEVICES AND METHODS, filed Jan. 9, 2009, which are incorporated herein by reference in their entireties. This application is a continuation-in-part of U.S. patent application Ser. No. 13/112,631, titled, VESSEL CLOSURE DEVICES, SYSTEMS, AND METHODS, filed May 20, 2011, which is a continuation-in-part of U.S. patent application Ser. No. 12/684,470, titled CLOSURE DEVICES, SYSTEMS, AND METHODS, filed Jan. 8, 2010, which claims the benefit of U.S. Provisional Application No. 61/143,751, titled VESSEL CLOSURE DEVICES AND METHODS, filed Jan. 9, 2009, which are incorporated herein by reference in their entireties. This application claims the benefit of U.S. Provisional Application No. 61/759,693, titled METHOD AND APPARATUS FOR PERCUTANEOUS TREATMENT OF A BLOOD VESSEL, filed Feb. 1, 2013, which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61143751 | Jan 2009 | US | |
| 61759693 | Feb 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13112618 | May 2011 | US |
| Child | 13837801 | US | |
| Parent | 12684470 | Jan 2010 | US |
| Child | 13112618 | US | |
| Parent | 13112631 | May 2011 | US |
| Child | 12684470 | US | |
| Parent | 12684470 | Jan 2010 | US |
| Child | 13112631 | US |
